Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsHere we select some of the classical literature in the field of chimeric antigen receptor technology. It is hoped that these reviews and research articles will help you to understand CAR technology quickly and keep up with the cutting edge development of this area.
Expert opinion on biological therapy 15, no. 8 (2015): 1145-1154.
Chmielewski, Markus, and Hinrich Abken.
Described a fourth generation car design named TRUCKs, which is CAR with inducible release of a transgenic payload.
Cancer discovery 3, no. 4 (2013): 388-398.
Sadelain, Michel, Renier Brentjens, and Isabelle Rivière.
This review concluded the basic principles of chimeric antigen receptor design.
Leukemia 24, no. 6 (2010): 1160-1170.
Hoyos, Valentina, Barbara Savoldo, Concetta Quintarelli, Aruna Mahendravada, Ming Zhang, Juan Vera, Helen E. Heslop, Cliona M. Rooney, Malcolm K. Brenner, and Gianpietro Dotti.
This study introduced a novel CAR-T construct that added a interleukin-15 (IL-15) gene and an inducible caspase-9-based suicide gene (iC9/CAR.19/IL-15) which gets greater numeric expansion upon antigen stimulation and improved antitumor effects in vivo. This is a fourth generation car t design.
Cancer research 71, no. 13 (2011): 4617-4627
Song, De-Gang, Qunrui Ye, Carmine Carpenito, Mathilde Poussin, Li-Ping Wang, Chunyan Ji, Mariangela Figini, Carl H. June, George Coukos, and Daniel J. Powell.
Study of the importance of costimulative signaling domain in car t cell therapy. This is the second generation car t design
Blood 119, no. 24 (2012): 5697-5705.
Torikai, Hiroki, Andreas Reik, Pei-Qi Liu, Yuanyue Zhou, Ling Zhang, Sourindra Maiti, Helen Huls et al.
This work introduced an universal allogeneic TAA-specific CAR-T cells from one donor that might be administered to multiple recipients. This was achieved by genetically editing CD19-specific CAR T cells using the Sleeping Beauty system to stably introduce the CD19-specific CAR with subsequent permanent deletion of α or β TCR chains with designer zinc finger nuclease.
Journal of the American Chemical Society 137.8 (2015): 2832-2835.
Kim, Min Soo, Jennifer SY Ma, Hwayoung Yun, Yu Cao, Ji Young Kim, Victor Chi, Danling Wang et al.
This work has a very smart design that use a bispecific small molecule as an adaptor which have the ability of controling car-t cell specificity to target tumor cells. This paper demonstrated a novel therapeutic approach that combines the dose titratability of small molecules with the potency of CAR-T cell therapy.
Molecular Therapy-Oncolytics 2 (2015): 15014.
VanSeggelen, Heather, et al.
A very interesting work that combine Chimeric antigen receptor with oncolytics virus. Use CAR-T cell as a targeting delivery system to deliver oncolytics virus into target tumor cells.
EMBO molecular medicine (2016): e201505869.
Jin, Chuan, Grammatiki Fotaki, Mohanraj Ramachandran, Berith Nilsson, Magnus Essand, and Di Yu.
This article present a novel episomal and long-term cell engineering technology. It is based on combining a non-integrating lentiviral (NILV) vector, wherein the integrase is mutated, and a scaffold/matrix attachment region (S/MAR) element, which anchors the episomal circularized DNA to the host cell genome without integration. These findings increase the safety level of T-cell engineering and can offer improved safety for engineering of other cell types
Cancer immunology research 3, no. 2 (2015): 125-135.
Hudecek, Michael, Daniel Sommermeyer, Paula L. Kosasih, Anne Silva-Benedict, Lingfeng Liu, Christoph Rader, Michael C. Jensen, and Stanley R. Riddell.
This study examining the length and composition of the extracellular spacer domain for CARs that target different cell surface molecules demonstrates that the length of this region can be tailored for optimal CAR function and identifies mutations in immunoglobulin Fc spacers that are necessary to abrogate Fc receptor binding.
Journal of hematology & oncology 10.1 (2017): 68.
Qin, Le, Yunxin Lai, Ruocong Zhao, Xinru Wei, Jianyu Weng, Peilong Lai, Baiheng Li et al.
This article discussed the importance of non-signaling extracellular modules (the hinge domain) on the expansion and therapeutic efficacy of CARs.
Nature reviews cancer 16.9 (2016): 566-581.
Fesnak, Andrew D., Carl H. June, and Bruce L. Levine.
This Review describe some of the most recent and promising advances in engineered T cell therapy with a particular emphasis on what the next generation of T cell therapy is likely to entail. Highlight variours of new chimeric antigen receptor models and concepts.
Expert opinion on biological therapy 15, no. 8 (2015): 1145-1154.
Chmielewski, Markus, and Hinrich Abken.
Described a fourth generation car design named TRUCKs, which is CAR with inducible release of a transgenic payload.
Cancer discovery 3, no. 4 (2013): 388-398.
Sadelain, Michel, Renier Brentjens, and Isabelle Rivière.
This review concluded the basic principles of chimeric antigen receptor design.
Leukemia 24, no. 6 (2010): 1160-1170.
Hoyos, Valentina, Barbara Savoldo, Concetta Quintarelli, Aruna Mahendravada, Ming Zhang, Juan Vera, Helen E. Heslop, Cliona M. Rooney, Malcolm K. Brenner, and Gianpietro Dotti.
This study introduced a novel CAR-T construct that added a interleukin-15 (IL-15) gene and an inducible caspase-9-based suicide gene (iC9/CAR.19/IL-15) which gets greater numeric expansion upon antigen stimulation and improved antitumor effects in vivo. This is a fourth generation car t design.
Cancer research 71, no. 13 (2011): 4617-4627
Song, De-Gang, Qunrui Ye, Carmine Carpenito, Mathilde Poussin, Li-Ping Wang, Chunyan Ji, Mariangela Figini, Carl H. June, George Coukos, and Daniel J. Powell.
Study of the importance of costimulative signaling domain in car t cell therapy. This is the second generation car t design
Blood 119, no. 24 (2012): 5697-5705.
Torikai, Hiroki, Andreas Reik, Pei-Qi Liu, Yuanyue Zhou, Ling Zhang, Sourindra Maiti, Helen Huls et al.
This work introduced an universal allogeneic TAA-specific CAR-T cells from one donor that might be administered to multiple recipients. This was achieved by genetically editing CD19-specific CAR T cells using the Sleeping Beauty system to stably introduce the CD19-specific CAR with subsequent permanent deletion of α or β TCR chains with designer zinc finger nuclease.
Journal of the American Chemical Society 137.8 (2015): 2832-2835.
Kim, Min Soo, Jennifer SY Ma, Hwayoung Yun, Yu Cao, Ji Young Kim, Victor Chi, Danling Wang et al.
This work has a very smart design that use a bispecific small molecule as an adaptor which have the ability of controling car-t cell specificity to target tumor cells. This paper demonstrated a novel therapeutic approach that combines the dose titratability of small molecules with the potency of CAR-T cell therapy.
Molecular Therapy-Oncolytics 2 (2015): 15014.
VanSeggelen, Heather, et al.
A very interesting work that combine Chimeric antigen receptor with oncolytics virus. Use CAR-T cell as a targeting delivery system to deliver oncolytics virus into target tumor cells.
EMBO molecular medicine (2016): e201505869.
Jin, Chuan, Grammatiki Fotaki, Mohanraj Ramachandran, Berith Nilsson, Magnus Essand, and Di Yu.
This article present a novel episomal and long-term cell engineering technology. It is based on combining a non-integrating lentiviral (NILV) vector, wherein the integrase is mutated, and a scaffold/matrix attachment region (S/MAR) element, which anchors the episomal circularized DNA to the host cell genome without integration. These findings increase the safety level of T-cell engineering and can offer improved safety for engineering of other cell types
Cancer immunology research 3, no. 2 (2015): 125-135.
Hudecek, Michael, Daniel Sommermeyer, Paula L. Kosasih, Anne Silva-Benedict, Lingfeng Liu, Christoph Rader, Michael C. Jensen, and Stanley R. Riddell.
This study examining the length and composition of the extracellular spacer domain for CARs that target different cell surface molecules demonstrates that the length of this region can be tailored for optimal CAR function and identifies mutations in immunoglobulin Fc spacers that are necessary to abrogate Fc receptor binding.
Journal of hematology & oncology 10.1 (2017): 68.
Qin, Le, Yunxin Lai, Ruocong Zhao, Xinru Wei, Jianyu Weng, Peilong Lai, Baiheng Li et al.
This article discussed the importance of non-signaling extracellular modules (the hinge domain) on the expansion and therapeutic efficacy of CARs.
Nature reviews cancer 16.9 (2016): 566-581.
Fesnak, Andrew D., Carl H. June, and Bruce L. Levine.
This Review describe some of the most recent and promising advances in engineered T cell therapy with a particular emphasis on what the next generation of T cell therapy is likely to entail. Highlight variours of new chimeric antigen receptor models and concepts.
Expert opinion on biological therapy 15, no. 8 (2015): 1145-1154.
Chmielewski, Markus, and Hinrich Abken.
Described a fourth generation car design named TRUCKs, which is CAR with inducible release of a transgenic payload.
Cancer discovery 3, no. 4 (2013): 388-398.
Sadelain, Michel, Renier Brentjens, and Isabelle Rivière.
This review concluded the basic principles of chimeric antigen receptor design.
Leukemia 24, no. 6 (2010): 1160-1170.
Hoyos, Valentina, Barbara Savoldo, Concetta Quintarelli, Aruna Mahendravada, Ming Zhang, Juan Vera, Helen E. Heslop, Cliona M. Rooney, Malcolm K. Brenner, and Gianpietro Dotti.
This study introduced a novel CAR-T construct that added a interleukin-15 (IL-15) gene and an inducible caspase-9-based suicide gene (iC9/CAR.19/IL-15) which gets greater numeric expansion upon antigen stimulation and improved antitumor effects in vivo. This is a fourth generation car t design.
Cancer research 71, no. 13 (2011): 4617-4627
Song, De-Gang, Qunrui Ye, Carmine Carpenito, Mathilde Poussin, Li-Ping Wang, Chunyan Ji, Mariangela Figini, Carl H. June, George Coukos, and Daniel J. Powell.
Study of the importance of costimulative signaling domain in car t cell therapy. This is the second generation car t design
Blood 119, no. 24 (2012): 5697-5705.
Torikai, Hiroki, Andreas Reik, Pei-Qi Liu, Yuanyue Zhou, Ling Zhang, Sourindra Maiti, Helen Huls et al.
This work introduced an universal allogeneic TAA-specific CAR-T cells from one donor that might be administered to multiple recipients. This was achieved by genetically editing CD19-specific CAR T cells using the Sleeping Beauty system to stably introduce the CD19-specific CAR with subsequent permanent deletion of α or β TCR chains with designer zinc finger nuclease.
Journal of the American Chemical Society 137.8 (2015): 2832-2835.
Kim, Min Soo, Jennifer SY Ma, Hwayoung Yun, Yu Cao, Ji Young Kim, Victor Chi, Danling Wang et al.
This work has a very smart design that use a bispecific small molecule as an adaptor which have the ability of controling car-t cell specificity to target tumor cells. This paper demonstrated a novel therapeutic approach that combines the dose titratability of small molecules with the potency of CAR-T cell therapy.
Molecular Therapy-Oncolytics 2 (2015): 15014.
VanSeggelen, Heather, et al.
A very interesting work that combine Chimeric antigen receptor with oncolytics virus. Use CAR-T cell as a targeting delivery system to deliver oncolytics virus into target tumor cells.
EMBO molecular medicine (2016): e201505869.
Jin, Chuan, Grammatiki Fotaki, Mohanraj Ramachandran, Berith Nilsson, Magnus Essand, and Di Yu.
This article present a novel episomal and long-term cell engineering technology. It is based on combining a non-integrating lentiviral (NILV) vector, wherein the integrase is mutated, and a scaffold/matrix attachment region (S/MAR) element, which anchors the episomal circularized DNA to the host cell genome without integration. These findings increase the safety level of T-cell engineering and can offer improved safety for engineering of other cell types
Cancer immunology research 3, no. 2 (2015): 125-135.
Hudecek, Michael, Daniel Sommermeyer, Paula L. Kosasih, Anne Silva-Benedict, Lingfeng Liu, Christoph Rader, Michael C. Jensen, and Stanley R. Riddell.
This study examining the length and composition of the extracellular spacer domain for CARs that target different cell surface molecules demonstrates that the length of this region can be tailored for optimal CAR function and identifies mutations in immunoglobulin Fc spacers that are necessary to abrogate Fc receptor binding.
Journal of hematology & oncology 10.1 (2017): 68.
Qin, Le, Yunxin Lai, Ruocong Zhao, Xinru Wei, Jianyu Weng, Peilong Lai, Baiheng Li et al.
This article discussed the importance of non-signaling extracellular modules (the hinge domain) on the expansion and therapeutic efficacy of CARs.
Nature reviews cancer 16.9 (2016): 566-581.
Fesnak, Andrew D., Carl H. June, and Bruce L. Levine.
This Review describe some of the most recent and promising advances in engineered T cell therapy with a particular emphasis on what the next generation of T cell therapy is likely to entail. Highlight variours of new chimeric antigen receptor models and concepts.
Expert opinion on biological therapy 15, no. 8 (2015): 1145-1154.
Chmielewski, Markus, and Hinrich Abken.
Described a fourth generation car design named TRUCKs, which is CAR with inducible release of a transgenic payload.
Cancer discovery 3, no. 4 (2013): 388-398.
Sadelain, Michel, Renier Brentjens, and Isabelle Rivière.
This review concluded the basic principles of chimeric antigen receptor design.
Leukemia 24, no. 6 (2010): 1160-1170.
Hoyos, Valentina, Barbara Savoldo, Concetta Quintarelli, Aruna Mahendravada, Ming Zhang, Juan Vera, Helen E. Heslop, Cliona M. Rooney, Malcolm K. Brenner, and Gianpietro Dotti.
This study introduced a novel CAR-T construct that added a interleukin-15 (IL-15) gene and an inducible caspase-9-based suicide gene (iC9/CAR.19/IL-15) which gets greater numeric expansion upon antigen stimulation and improved antitumor effects in vivo. This is a fourth generation car t design.
Cancer research 71, no. 13 (2011): 4617-4627
Song, De-Gang, Qunrui Ye, Carmine Carpenito, Mathilde Poussin, Li-Ping Wang, Chunyan Ji, Mariangela Figini, Carl H. June, George Coukos, and Daniel J. Powell.
Study of the importance of costimulative signaling domain in car t cell therapy. This is the second generation car t design
Blood 119, no. 24 (2012): 5697-5705.
Torikai, Hiroki, Andreas Reik, Pei-Qi Liu, Yuanyue Zhou, Ling Zhang, Sourindra Maiti, Helen Huls et al.
This work introduced an universal allogeneic TAA-specific CAR-T cells from one donor that might be administered to multiple recipients. This was achieved by genetically editing CD19-specific CAR T cells using the Sleeping Beauty system to stably introduce the CD19-specific CAR with subsequent permanent deletion of α or β TCR chains with designer zinc finger nuclease.
Journal of the American Chemical Society 137.8 (2015): 2832-2835.
Kim, Min Soo, Jennifer SY Ma, Hwayoung Yun, Yu Cao, Ji Young Kim, Victor Chi, Danling Wang et al.
This work has a very smart design that use a bispecific small molecule as an adaptor which have the ability of controling car-t cell specificity to target tumor cells. This paper demonstrated a novel therapeutic approach that combines the dose titratability of small molecules with the potency of CAR-T cell therapy.
Molecular Therapy-Oncolytics 2 (2015): 15014.
VanSeggelen, Heather, et al.
A very interesting work that combine Chimeric antigen receptor with oncolytics virus. Use CAR-T cell as a targeting delivery system to deliver oncolytics virus into target tumor cells.
EMBO molecular medicine (2016): e201505869.
Jin, Chuan, Grammatiki Fotaki, Mohanraj Ramachandran, Berith Nilsson, Magnus Essand, and Di Yu.
This article present a novel episomal and long-term cell engineering technology. It is based on combining a non-integrating lentiviral (NILV) vector, wherein the integrase is mutated, and a scaffold/matrix attachment region (S/MAR) element, which anchors the episomal circularized DNA to the host cell genome without integration. These findings increase the safety level of T-cell engineering and can offer improved safety for engineering of other cell types
Cancer immunology research 3, no. 2 (2015): 125-135.
Hudecek, Michael, Daniel Sommermeyer, Paula L. Kosasih, Anne Silva-Benedict, Lingfeng Liu, Christoph Rader, Michael C. Jensen, and Stanley R. Riddell.
This study examining the length and composition of the extracellular spacer domain for CARs that target different cell surface molecules demonstrates that the length of this region can be tailored for optimal CAR function and identifies mutations in immunoglobulin Fc spacers that are necessary to abrogate Fc receptor binding.
Journal of hematology & oncology 10.1 (2017): 68.
Qin, Le, Yunxin Lai, Ruocong Zhao, Xinru Wei, Jianyu Weng, Peilong Lai, Baiheng Li et al.
This article discussed the importance of non-signaling extracellular modules (the hinge domain) on the expansion and therapeutic efficacy of CARs.
Nature reviews cancer 16.9 (2016): 566-581.
Fesnak, Andrew D., Carl H. June, and Bruce L. Levine.
This Review describe some of the most recent and promising advances in engineered T cell therapy with a particular emphasis on what the next generation of T cell therapy is likely to entail. Highlight variours of new chimeric antigen receptor models and concepts.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
